HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the JonesTrading Healthcare Seaside Summit occurring July 14-16, 2024, in San Diego, California.
Details of the presentations are as follows:
Presentation Date: Monday, July 15, 2024
Time: 1:45 p.m. PDT
Webcast Registration: https://wsw.com/webcast/jones/fblg/1793925
Links to the replay will be accessible under the “News & Events” tab on the Investor Relations page on the company’s website at https://ir.fibrobiologics.com/news-events/ir-calendar.
For more information, please visit FibroBiologics' website or email FibroBiologics at This email address is being protected from spambots. You need JavaScript enabled to view it..
About FibroBiologics
Based in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.09 |
| Daily Change: | 0.13 13.89 |
| Daily Volume: | 462,611 |
| Market Cap: | US$38.370M |
April 02, 2025 March 31, 2025 March 04, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
